Machina Capital S.A.S. cut its holdings in shares of Celgene Co. (NASDAQ:CELG) by 17.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 26,192 shares of the biopharmaceutical company’s stock after selling 5,721 shares during the period. Celgene makes up approximately 0.9% of Machina Capital S.A.S.’s investment portfolio, making the stock its 15th largest holding. Machina Capital S.A.S.’s holdings in Celgene were worth $2,421,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Bristlecone Advisors LLC bought a new position in Celgene during the second quarter worth about $356,000. Canandaigua National Bank & Trust Co. lifted its holdings in Celgene by 46.3% during the second quarter. Canandaigua National Bank & Trust Co. now owns 14,370 shares of the biopharmaceutical company’s stock worth $1,328,000 after acquiring an additional 4,548 shares in the last quarter. Altium Wealth Management LLC lifted its holdings in Celgene by 6.3% during the second quarter. Altium Wealth Management LLC now owns 9,542 shares of the biopharmaceutical company’s stock worth $882,000 after acquiring an additional 562 shares in the last quarter. Moors & Cabot Inc. lifted its holdings in Celgene by 12.9% during the second quarter. Moors & Cabot Inc. now owns 17,560 shares of the biopharmaceutical company’s stock worth $1,622,000 after acquiring an additional 2,010 shares in the last quarter. Finally, NuWave Investment Management LLC lifted its holdings in Celgene by 1,835.7% during the second quarter. NuWave Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 1,542 shares in the last quarter. Hedge funds and other institutional investors own 74.84% of the company’s stock.

CELG has been the topic of several recent analyst reports. Zacks Investment Research lowered Phoenix New Media from a “hold” rating to a “sell” rating in a report on Tuesday, July 23rd. Cantor Fitzgerald set a $11.00 target price on TAIWAN LIPOSOME/S and gave the stock a “buy” rating in a report on Friday, April 5th. Sanford C. Bernstein reiterated a “sell” rating on shares of easyJet in a report on Monday, April 1st. William Blair started coverage on Q2 in a report on Monday, April 1st. They set an “outperform” rating and a $69.71 target price on the stock. Finally, BidaskClub raised Xilinx from a “hold” rating to a “buy” rating in a research note on Wednesday, July 24th. Two investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $94.81.

NASDAQ CELG traded down $0.27 during trading on Tuesday, reaching $92.72. 70,273 shares of the company’s stock were exchanged, compared to its average volume of 3,638,123. The firm’s 50 day simple moving average is $93.67. The firm has a market capitalization of $65.42 billion, a PE ratio of 12.19, a P/E/G ratio of 0.44 and a beta of 1.45. The company has a quick ratio of 2.66, a current ratio of 2.78 and a debt-to-equity ratio of 2.42. Celgene Co. has a fifty-two week low of $58.59 and a fifty-two week high of $98.97.

About Celgene

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Recommended Story: Oversold

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.